Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Tietueen suppeat tiedot
dc.contributor.authorEva Prescott
dc.contributor.authorJohn Pernow
dc.contributor.authorAntti Saraste
dc.contributor.authorAxel Åkerblom
dc.contributor.authorOskar Angerås
dc.contributor.authorDavid Erlinge
dc.contributor.authorErik L. Grove
dc.contributor.authorMarja Hedman
dc.contributor.authorLisette O. Jensen
dc.contributor.authorSara Svedlund
dc.contributor.authorMagnus Kjaer
dc.contributor.authorMaria Lagerström-Fermér
dc.contributor.authorLi-Ming Gan
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.40502528769
dc.converis.publication-id50181904
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/50181904
dc.date.accessioned2022-10-28T13:23:04Z
dc.date.available2022-10-28T13:23:04Z
dc.description.abstractlevels is the primary efficacy outcome. FLAVOUR also aims to evaluate whether AZD5718 can improve coronary microvascular function, as measured by transthoracic colour Doppler-assisted coronary flow velocity reserve. Centrally pretrained study sonographers use standardized protocols and equipment. Additional outcomes include assessment of comprehensive echocardiographic parameters (including coronary flow, global strain, early diastolic strain rate and left ventricular ejection fraction), arterial stiffness, biomarkers, health-related quality of life, and safety. Specific anti-inflammatory therapies may represent novel promising treatments to reduce residual risk in patients with coronary artery disease. By combining primary pharmacodynamic and secondary cardiovascular surrogate efficacy outcomes, FLAVOUR aims to investigate the mechanistic basis and potential benefits of AZD5718 treatment in patients with coronary artery disease.
dc.identifier.eissn2451-8654
dc.identifier.jour-issn2451-8654
dc.identifier.olddbid181698
dc.identifier.oldhandle10024/164792
dc.identifier.urihttps://www.utupub.fi/handle/11111/53042
dc.identifier.urnURN:NBN:fi-fe2021042826771
dc.language.isoen
dc.okm.affiliatedauthorSaraste, Antti
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier Inc.
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumber100629
dc.relation.doi10.1016/j.conctc.2020.100629
dc.relation.ispartofjournalContemporary Clinical Trials Communications
dc.relation.volume19
dc.source.identifierhttps://www.utupub.fi/handle/10024/164792
dc.titleDesign and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Name:
1-s2.0-S2451865420301137-main.pdf
Size:
4 MB
Format:
Adobe Portable Document Format
Description:
Publisher's version
Lataa

Kokoelmat

Rinnakkaistallenteet